APO Research
Talk to an analyst

APO RESEARCH · REPORT

Encephalitis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Encephalitis Vaccine Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchEncephalitis Vaccine Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Encephalitis Vaccine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Encephalitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Encephalitis Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Encephalitis Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Encephalitis Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Encephalitis Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Encephalitis Vaccine market include Biken, Valneva, Tiantan Biological Products, Chengdu Institute of Biological Products, Lanzhou Institute of Biological Products, Liaoning Chengda, Sanofi Pasteur, Wuhan Institute of Biological Products and Yisheng Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Encephalitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Encephalitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Encephalitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Encephalitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Encephalitis Vaccine Segment by Company

Biken

Valneva

Tiantan Biological Products

Chengdu Institute of Biological Products

Lanzhou Institute of Biological Products

Liaoning Chengda

Sanofi Pasteur

Wuhan Institute of Biological Products

Yisheng Bio

Changchun Institute of Biological Products

Zhejiang Tianyuan Bio-Pharmaceutical

Encephalitis Vaccine Segment by Type

Inactivated Vaccine

Live Attenuated Vaccine

Encephalitis Vaccine Segment by Application

Child

Adult

Encephalitis Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Encephalitis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Encephalitis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Encephalitis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Encephalitis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Encephalitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Encephalitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Encephalitis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Encephalitis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Encephalitis Vaccine industry.

Chapter 3: Detailed analysis of Encephalitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Encephalitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Encephalitis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Encephalitis Vaccine Industry Trends Table 2. Encephalitis Vaccine Industry Drivers Table 3. Encephalitis Vaccine Industry Opportunities and Challenges Table 4. Encephalitis Vaccine Industry Restraints Table 5. Global Encephalitis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Encephalitis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Encephalitis Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Encephalitis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Encephalitis Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Encephalitis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Encephalitis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Encephalitis Vaccine Company, Product Type & Application Table 13. Global Encephalitis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Encephalitis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Inactivated Vaccine Table 18. Significant Companies of Live Attenuated Vaccine Table 19. Global Encephalitis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Encephalitis Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Encephalitis Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Encephalitis Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Encephalitis Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Encephalitis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Encephalitis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Encephalitis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Encephalitis Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Encephalitis Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Child Table 30. Significant Companies of Adult Table 31. Global Encephalitis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Encephalitis Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Encephalitis Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Encephalitis Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Encephalitis Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Encephalitis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Encephalitis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Encephalitis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Encephalitis Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Encephalitis Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Encephalitis Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Encephalitis Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Encephalitis Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Encephalitis Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Encephalitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Encephalitis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Encephalitis Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Encephalitis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Encephalitis Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Encephalitis Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Encephalitis Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Encephalitis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Encephalitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Encephalitis Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Encephalitis Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Encephalitis Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Encephalitis Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Encephalitis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Encephalitis Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Encephalitis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Encephalitis Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Biken Company Information Table 64. Biken Business Overview Table 65. Biken Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Biken Encephalitis Vaccine Product Portfolio Table 67. Biken Recent Development Table 68. Valneva Company Information Table 69. Valneva Business Overview Table 70. Valneva Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Valneva Encephalitis Vaccine Product Portfolio Table 72. Valneva Recent Development Table 73. Tiantan Biological Products Company Information Table 74. Tiantan Biological Products Business Overview Table 75. Tiantan Biological Products Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Tiantan Biological Products Encephalitis Vaccine Product Portfolio Table 77. Tiantan Biological Products Recent Development Table 78. Chengdu Institute of Biological Products Company Information Table 79. Chengdu Institute of Biological Products Business Overview Table 80. Chengdu Institute of Biological Products Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Chengdu Institute of Biological Products Encephalitis Vaccine Product Portfolio Table 82. Chengdu Institute of Biological Products Recent Development Table 83. Lanzhou Institute of Biological Products Company Information Table 84. Lanzhou Institute of Biological Products Business Overview Table 85. Lanzhou Institute of Biological Products Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Lanzhou Institute of Biological Products Encephalitis Vaccine Product Portfolio Table 87. Lanzhou Institute of Biological Products Recent Development Table 88. Liaoning Chengda Company Information Table 89. Liaoning Chengda Business Overview Table 90. Liaoning Chengda Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Liaoning Chengda Encephalitis Vaccine Product Portfolio Table 92. Liaoning Chengda Recent Development Table 93. Sanofi Pasteur Company Information Table 94. Sanofi Pasteur Business Overview Table 95. Sanofi Pasteur Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sanofi Pasteur Encephalitis Vaccine Product Portfolio Table 97. Sanofi Pasteur Recent Development Table 98. Wuhan Institute of Biological Products Company Information Table 99. Wuhan Institute of Biological Products Business Overview Table 100. Wuhan Institute of Biological Products Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Wuhan Institute of Biological Products Encephalitis Vaccine Product Portfolio Table 102. Wuhan Institute of Biological Products Recent Development Table 103. Yisheng Bio Company Information Table 104. Yisheng Bio Business Overview Table 105. Yisheng Bio Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Yisheng Bio Encephalitis Vaccine Product Portfolio Table 107. Yisheng Bio Recent Development Table 108. Changchun Institute of Biological Products Company Information Table 109. Changchun Institute of Biological Products Business Overview Table 110. Changchun Institute of Biological Products Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Changchun Institute of Biological Products Encephalitis Vaccine Product Portfolio Table 112. Changchun Institute of Biological Products Recent Development Table 113. Zhejiang Tianyuan Bio-Pharmaceutical Company Information Table 114. Zhejiang Tianyuan Bio-Pharmaceutical Business Overview Table 115. Zhejiang Tianyuan Bio-Pharmaceutical Encephalitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Zhejiang Tianyuan Bio-Pharmaceutical Encephalitis Vaccine Product Portfolio Table 117. Zhejiang Tianyuan Bio-Pharmaceutical Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Encephalitis Vaccine Distributors List Table 121. Encephalitis Vaccine Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Encephalitis Vaccine Product Image Figure 2. Global Encephalitis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Encephalitis Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Encephalitis Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Encephalitis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Inactivated Vaccine Image Figure 10. Live Attenuated Vaccine Image Figure 11. Global Encephalitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Encephalitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Encephalitis Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Encephalitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Encephalitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Encephalitis Vaccine Sales Value Share by Type (2021-2032) Figure 17. Child Image Figure 18. Adult Image Figure 19. Global Encephalitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Encephalitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Encephalitis Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Encephalitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Encephalitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Encephalitis Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Encephalitis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Encephalitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Encephalitis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Encephalitis Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Encephalitis Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Live Attenuated Vaccine
Applications
  • Child
  • Adult
Companies covered
  • Biken
  • Valneva
  • Tiantan Biological Products
  • Chengdu Institute of Biological Products
  • Lanzhou Institute of Biological Products
  • Liaoning Chengda
  • Sanofi Pasteur
  • Wuhan Institute of Biological Products
  • Yisheng Bio
  • Changchun Institute of Biological Products
  • Zhejiang Tianyuan Bio-Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Encephalitis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Encephalitis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Encephalitis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Encephalitis Vaccine Market Dynamics
  1. 2.1 Encephalitis Vaccine Industry Trends
  2. 2.2 Encephalitis Vaccine Industry Drivers
  3. 2.3 Encephalitis Vaccine Industry Opportunities and Challenges
  4. 2.4 Encephalitis Vaccine Industry Restraints
3 Encephalitis Vaccine Market by Company
  1. 3.1 Global Encephalitis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Encephalitis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Encephalitis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Encephalitis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Encephalitis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Encephalitis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Encephalitis Vaccine Company Product Type and Application
  8. 3.8 Global Encephalitis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Encephalitis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Encephalitis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Encephalitis Vaccine Market by Type
  1. 4.1 Encephalitis Vaccine Type Introduction
  2. 4.1.1 Inactivated Vaccine
  3. 4.1.2 Live Attenuated Vaccine
  4. 4.2 Global Encephalitis Vaccine Sales Volume by Type
  5. 4.2.1 Global Encephalitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Encephalitis Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Encephalitis Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Encephalitis Vaccine Sales Value by Type
  9. 4.3.1 Global Encephalitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Encephalitis Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Encephalitis Vaccine Sales Value Share by Type (2021-2032)
5 Encephalitis Vaccine Market by Application
  1. 5.1 Encephalitis Vaccine Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Adult
  4. 5.2 Global Encephalitis Vaccine Sales Volume by Application
  5. 5.2.1 Global Encephalitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Encephalitis Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Encephalitis Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Encephalitis Vaccine Sales Value by Application
  9. 5.3.1 Global Encephalitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Encephalitis Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Encephalitis Vaccine Sales Value Share by Application (2021-2032)
6 Encephalitis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Encephalitis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Encephalitis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Encephalitis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Encephalitis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Encephalitis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Encephalitis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Encephalitis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Encephalitis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Encephalitis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Encephalitis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Encephalitis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Encephalitis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Encephalitis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Encephalitis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Encephalitis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Encephalitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Encephalitis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Encephalitis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Encephalitis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Encephalitis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Encephalitis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Encephalitis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biken
  2. 8.1.1 Biken Company Information
  3. 8.1.2 Biken Business Overview
  4. 8.1.3 Biken Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biken Encephalitis Vaccine Product Portfolio
  6. 8.1.5 Biken Recent Developments
  7. 8.2 Valneva
  8. 8.2.1 Valneva Company Information
  9. 8.2.2 Valneva Business Overview
  10. 8.2.3 Valneva Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Valneva Encephalitis Vaccine Product Portfolio
  12. 8.2.5 Valneva Recent Developments
  13. 8.3 Tiantan Biological Products
  14. 8.3.1 Tiantan Biological Products Company Information
  15. 8.3.2 Tiantan Biological Products Business Overview
  16. 8.3.3 Tiantan Biological Products Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tiantan Biological Products Encephalitis Vaccine Product Portfolio
  18. 8.3.5 Tiantan Biological Products Recent Developments
  19. 8.4 Chengdu Institute of Biological Products
  20. 8.4.1 Chengdu Institute of Biological Products Company Information
  21. 8.4.2 Chengdu Institute of Biological Products Business Overview
  22. 8.4.3 Chengdu Institute of Biological Products Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Institute of Biological Products Encephalitis Vaccine Product Portfolio
  24. 8.4.5 Chengdu Institute of Biological Products Recent Developments
  25. 8.5 Lanzhou Institute of Biological Products
  26. 8.5.1 Lanzhou Institute of Biological Products Company Information
  27. 8.5.2 Lanzhou Institute of Biological Products Business Overview
  28. 8.5.3 Lanzhou Institute of Biological Products Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lanzhou Institute of Biological Products Encephalitis Vaccine Product Portfolio
  30. 8.5.5 Lanzhou Institute of Biological Products Recent Developments
  31. 8.6 Liaoning Chengda
  32. 8.6.1 Liaoning Chengda Company Information
  33. 8.6.2 Liaoning Chengda Business Overview
  34. 8.6.3 Liaoning Chengda Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Liaoning Chengda Encephalitis Vaccine Product Portfolio
  36. 8.6.5 Liaoning Chengda Recent Developments
  37. 8.7 Sanofi Pasteur
  38. 8.7.1 Sanofi Pasteur Company Information
  39. 8.7.2 Sanofi Pasteur Business Overview
  40. 8.7.3 Sanofi Pasteur Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Pasteur Encephalitis Vaccine Product Portfolio
  42. 8.7.5 Sanofi Pasteur Recent Developments
  43. 8.8 Wuhan Institute of Biological Products
  44. 8.8.1 Wuhan Institute of Biological Products Company Information
  45. 8.8.2 Wuhan Institute of Biological Products Business Overview
  46. 8.8.3 Wuhan Institute of Biological Products Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Wuhan Institute of Biological Products Encephalitis Vaccine Product Portfolio
  48. 8.8.5 Wuhan Institute of Biological Products Recent Developments
  49. 8.9 Yisheng Bio
  50. 8.9.1 Yisheng Bio Company Information
  51. 8.9.2 Yisheng Bio Business Overview
  52. 8.9.3 Yisheng Bio Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Yisheng Bio Encephalitis Vaccine Product Portfolio
  54. 8.9.5 Yisheng Bio Recent Developments
  55. 8.10 Changchun Institute of Biological Products
  56. 8.10.1 Changchun Institute of Biological Products Company Information
  57. 8.10.2 Changchun Institute of Biological Products Business Overview
  58. 8.10.3 Changchun Institute of Biological Products Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Changchun Institute of Biological Products Encephalitis Vaccine Product Portfolio
  60. 8.10.5 Changchun Institute of Biological Products Recent Developments
  61. 8.11 Zhejiang Tianyuan Bio-Pharmaceutical
  62. 8.11.1 Zhejiang Tianyuan Bio-Pharmaceutical Company Information
  63. 8.11.2 Zhejiang Tianyuan Bio-Pharmaceutical Business Overview
  64. 8.11.3 Zhejiang Tianyuan Bio-Pharmaceutical Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Zhejiang Tianyuan Bio-Pharmaceutical Encephalitis Vaccine Product Portfolio
  66. 8.11.5 Zhejiang Tianyuan Bio-Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Encephalitis Vaccine Value Chain Analysis
  2. 9.1.1 Encephalitis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Encephalitis Vaccine Sales Mode & Process
  6. 9.2 Encephalitis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Encephalitis Vaccine Distributors
  9. 9.2.3 Encephalitis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst